A Park Ave. doctor is among more than 350 nationally that is being warned by the Food and Drug Administration (FDA) that it could have purchased fake Botox from a Canadian supplier.
The FDA has sent letters to the medical practices claiming that they may have received unapproved medications, including unapproved versions of Botox.
The feds say the medications may be counterfeit, contaminated, improperly stored and transported, ineffective, and/or unsafe.
Medical practices that purchase and administer illegal and unapproved medications from foreign sources are placing patients at risk and potentially depriving them of proper treatment, according to the letter.
The FDA is asking medical practices stop administering the unapproved versions of Botox and any other products they have received from foreign suppliers owned and operated by Canada Drugs and known under the following names: Quality Specialty Products (QSP), A+ Health Supplies, QP Medical, Bridgewater Medical, or Clinical Care.
The FDA warns that many, if not all, of the products sold and distributed by these suppliers have not been approved.
The medications may also lack the required labels that ensure their appropriate and safe use. For example, unapproved botulinum toxin products may not contain the boxed warning. As a result, health care practitioners and patients may not be fully informed of the potential serious risk of harm or death from the use of the products.
The FDA has issued letters to medical practices in the United States that purchased unapproved medications from foreign suppliers five times this year.